TC Biopharm (Holdings) Plc
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bryan Leland Kobel
- Full Time Employees
- 41
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Maxim 1 Motherwell United Kingdom ML1 4WR
- IPO Date
- Feb 11, 2022
- CIK
- 0001872812
- Website
- tcbiopharm.com
- Similar Companies
- Business
- TC Biopharm (Holdings) Plc (TCBP) is a clinical-stage biopharmaceutical company that develops and commercializes allogeneic gamma delta T cell therapies and advanced CAR-T cell products for cancer treatment and infectious diseases. The company offers OmnImmune (TCB002), an unmodified allogeneic gamma-delta T cell therapy in phase 2/3 clinical trials for acute myeloid leukemia; ImmuniStim, an unmodified cell therapy for viral infections and solid tumors; and CAR-T therapies including TCB008 targeting CD19 for liquid tumors, as well as preclinical programs for mpox and other indications using its proprietary CryoTC frozen cell technology. Operations span the United Kingdom, United States, and Europe through its integrated model encompassing research, GMP manufacturing, and clinical translation from its headquarters in Motherwell, Scotland, where it was founded in 2013. Recent developments include signing a non-binding letter of intent in March 2025 to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved once-daily eye drop for glaucoma and ocular hypertension, expected to close in Q3 2025 and generate revenue in 2025; two additional non-binding LOIs for cell therapy acquisitions; a strategic partnership with a leading UK university for AI-driven donor screening in allogeneic therapies; collaboration with an infectious disease expert for mpox proof-of-concept trials; an $8 million capital raise in 2024; and a European Patent Office grant in August 2024 for modified gamma-delta cells in cancer and viral treatments.
TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
TCBP Announces Transition from Nasdaq to OTC Markets
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
TCBP to Implement ADS Ratio Change
TCBP Announces H5N1 Proof of Concept Studies Intention
TCBP to Present at Sequire Investor Summit 2025
TCBP Trading Continues Unabated on Nasdaq Stock Exchange
TCBP Provides Update on Acquisition Strategy and Current Targets
TCBP Issues 25% Stock Dividend
TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements